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Differences in the Acute Toxic Effects
of Breast Radiotherapy by Fractionation Schedule
Comparative Analysis of Physician-Assessed and
Patient-Reported Outcomes in a Large Multicenter Cohort
Reshma Jagsi, MD, DPhil; Kent A. Griffith, MS; Thomas P. Boike, MD; Eleanor Walker, MD; Teamour Nurushev, PhD;
Inga S. Grills, MD; Jean M. Moran, PhD; Mary Feng, MD; James Hayman, MD; Lori J. Pierce, MD
Invited Commentary page 941
IMPORTANCE Randomized trials have established the long-term safety and efficacy of

hypofractionated whole-breast radiotherapy, but little is known about the acute toxic effects
experienced by patients treated with hypofractionation as compared with conventional
fractionation, particularly in real-world settings and from the patient’s own perspective.
OBJECTIVE To evaluate prospectively collected data on acute toxic effects and

Author Audio Interview at
jamaoncology.com
Related article page 931
Supplemental content at
jamaoncology.com

patient-reported outcomes in a cohort treated with varying radiation fractionation schemes
in practices collaborating in the Michigan Radiation Oncology Quality Consortium (MROQC).
DESIGN, SETTING, AND PARTICIPANTS We compared toxic effects in patients receiving
hypofractionation (HF) vs conventional fractionation (CF) during treatment (through 7 days
after treatment) and in follow-up (posttreatment days 8-210), after adjustment for
sociodemographic, clinical, and treatment characteristics. The MROQC includes academic
and community radiation oncology practices across Michigan. All 2604 patients who received
adjuvant whole-breast radiotherapy after lumpectomy for unilateral breast cancer at MROQC
participating sites from October 2011 through June 2014 were registered; we analyzed 2309
for whom there was a comprehensive physician toxicity evaluation within 1 week of
completion of radiotherapy and at least 1 weekly toxicity evaluation during treatment.
EXPOSURES Hypofractionation vs CF.
MAIN OUTCOMES AND MEASURES Physicians reported dermatitis, pain, fatigue, and other
common toxic effects associated with breast radiotherapy at baseline, weekly during
radiotherapy, and in follow-up. Patients who consented also rated their own experiences,
including breast pain, fatigue, and being bothered by symptoms.
RESULTS Of the 2309 evaluable patients, 578 received HF. During treatment, after
adjustment for sociodemographic, clinical, and treatment factors, patients receiving CF had
significantly higher maximum physician-assessed skin reaction (moist desquamation, 28.5%
vs 6.6%, P < .001; grade ⱖ2 dermatitis, 62.6% vs 27.4%, P < .001), self-reported pain
(moderate/severe pain, 41.1% vs 24.2%, P = .003), burning/stinging bother (often/always,
38.7% vs 15.7%, P = .002), hurting bother (33.5% vs 16.0%, P = .001), swelling bother
(29.6% vs 15.7%, P = .03), and fatigue (29.7% vs 18.9%, P = .02) but slightly greater absence
of skin induration in follow-up (84.5% vs 81.2%, P = .02). No significant differences were
observed in any other measured outcomes during follow-up extending through 6 months.
CONCLUSIONS AND RELEVANCE Hypofractionation not only improves convenience but also
may reduce acute pain, fatigue, and the extent to which patients are bothered by dermatitis
in patients with breast cancer undergoing whole-breast radiotherapy.
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R

andomized trials have established that hypofractionated regimens of radiotherapy to the whole breast
can provide long-term disease control that is equivalent to the excellent outcomes of more protracted conventional fractionation schedules in selected patients undergoing lumpectomy for breast cancer. 1,2 Hypofractionation
might also result in lower rates of late toxic effects than conventional fractionation.2 Although the American Society for
Radiation Oncology has issued consensus guidelines 3
to identify patients in whom hypofractionation is appropriate and endorsed consideration of hypofractionation in its
Choosing Wisely campaign,4 uptake of hypofractionated
regimens has demonstrated considerable variability
worldwide5-8 and has been relatively slow within the United
States.9-11
The hypofractionated schedules evaluated in recent
trials have deliberately paired the increase in fraction size
with lower total dose, given concerns about toxicity when
large fraction sizes were used to deliver higher total doses to
the whole breast.12 Scholars have suggested that breast cancer cells may have a lower α to β ratio than typically ascribed
to tumor cells, which renders them vulnerable to larger dose
per fraction and allows for tumor control at lower total doses
than when dose per fraction is smaller. Because acutereacting normal tissues are expected to demonstrate toxic
effects that relate to total dose, with lesser dependence on
fraction size, it is possible that the use of schedules such as
42.5 Gy in 16 fractions or 40 Gy in 15 fractions might actually
result in lower rates of bothersome symptoms that typically
occur during and soon after radiation treatment, including
dermatitis, pain, and fatigue, with important implications
for quality of life. However, the reports of randomized trials
to date have provided little information comparing acute
toxic effects with hypofractionation as compared with conventional fractionation,13-17 and no evidence of comparative
effectiveness or patient-reported outcomes has been available from cohorts of patients treated outside the context of
clinical trials.
The Michigan Radiation Oncology Quality Consortium
(MROQC) is a multicenter, prospective collaboration through
which detailed clinical, sociodemographic, treatment, dosimetric, and outcomes data are collected for patients receiving adjuvant radiotherapy after lumpectomy at 18 centers in
the state of Michigan. 10 It is funded by Blue Cross Blue
Shield of Michigan, but data are collected on all eligible
patients within participating practices, regardless of insurance type. Because MROQC includes physician-assessed and
patient-reported toxicity information from a large cohort of
patients treated with varying fractionation schedules outside the context of selective and controlled clinical trials settings, it provides a unique opportunity to document in detail
the acute toxic effects experienced by patients receiving
breast radiotherapy in modern practice. It also allows for an
evaluation of the comparative effectiveness of hypofractionated regimens as compared with conventional fractionation
schedules in terms of the frequency and severity of acute
toxic effects that commonly occur during adjuvant wholebreast radiotherapy.
jamaoncology.com
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At a Glance
• Our consortium evaluated the acute toxic effects experienced by
patients treated with hypofractionated whole-breast
radiotherapy as compared with conventional fractionation using
both physician-assessed and patient-reported outcome
measures.
• During treatment, patients receiving conventionally fractionated
whole-breast radiotherapy had significantly higher maximum
physician-assessed skin reaction (grade ⱖ2 dermatitis, 62.6% vs
27.4%; P < .001).
• Patients treated with conventional fractionation also had higher
rates of self-reported breast pain than those treated with
hypofractionation (moderate/severe pain, 41.1% vs 24.2%;
P = .003).
• Hypofractionation not only improves convenience but is also
associated with less acute pain, fatigue, and dermatitis among
patients with breast cancer.

Methods
Sample
We considered a cohort of patients with breast cancer registered by MROQC (an institutional review board–approved
initiative with consent waiver) from its inception in October
2011 through June 2014. From the 2604 patients identified
as receiving adjuvant radiotherapy after lumpectomy for
unilateral breast cancer during that selection period, we limited the cohort to the 2318 for whom there was a comprehensive physician toxicity evaluation within 1 week of
completion of radiotherapy (which we defined as the “end of
treatment evaluation”), as well as at least 1 weekly toxicity
evaluation during treatment. We further excluded 9 patients
registered by newly participating institutions that had not
yet registered more than 10 patients, in order to allow for
quality control and analysis by institution. This left 2309
patients in the final sample for analysis of physicianevaluated outcomes during treatment. Follow-up physician
assessments, completed at visits between 8 and 210 days
after end of treatment, were available for 1781 of the 2309
patients.
Of the 2309 patients analyzed for physician-assessed outcomes during treatment, 1723 patients had completed at least
the comprehensive end-of-treatment questionnaire and at least
1 weekly questionnaire during treatment; these 1723 women
constituted the sample for analysis of patient-reported outcomes. Follow-up patient questionnaires, completed between 8 and 210 days after end of treatment, were available
for 1368 of these 1723 patients.

Measures
Physicians were asked to complete toxicity forms at baseline,
weekly during treatment, and approximately 3 months after
treatment, as well as during any other follow-up visits. These
physician toxicity forms (eAppendix 1 in the Supplement)
included lists of Common Terminology Criteria for Adverse
Events (CTCAE), version 4.0, toxicities commonly observed
(Reprinted) JAMA Oncology October 2015 Volume 1, Number 7
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during and after treatment. Weekly treatment forms evaluated breast pain, chest wall pain, radiation dermatitis,
lymphedema, and fatigue on the CTCAE grading scale (with
definitions provided). Physicians were also asked whether
the patient had moist desquamation and whether she had
dry desquamation. Forms for physician assessments at end
of treatment and in follow-up included all of these items, as
well as CTCAE grading for pruritus, skin induration, dyspnea, pleuritic pain, pneumonitis, pericarditis, and pericardial effusion.
Patients who consented to participate in patientreported outcomes collection were also given detailed questionnaires at these same time points (eAppendix 2 in the
Supplement). The questionnaires were developed using
standard techniques for survey design,18 including incorporation of existing validated instruments where possible and
evaluation using detailed cognitive pretesting.19 The weekly
treatment forms included ratings of pain from a 4-item
modified Brief Pain Inventory20 (modified to specify breast
pain), radiation skin reaction (using items developed specifically for this purpose), and bother related to the acute radiation reaction as assessed through an 8-item modified Skindex questionnaire 2 1 (specifying bother related to the
radiation reaction rather than the more general “skin condition” terminology in the original instrument). The end-oftreatment forms included these items and items evaluating
fatigue, satisfaction with treatment, and impact of radiotherapy adverse effects (using items developed in previous
work by our research group). Follow-up questionnaires
included the same measures of pain, skin reaction, and
bother related to radiation reaction, as well as the detailed
Breast Cancer Treatment Outcomes Scale.22 Of note, patientreported information collected on these questionnaires was
used for classification of patient race in this study, using
options provided by the investigators. Where patientreported information on race was missing, race was classified into these investigator-defined categories based on
review of medical records. Race was included as a covariate
because the primary acute toxic effect of breast radiotherapy
is dermatitis, which might manifest differently or be measured in systematically different ways by race (eg, because
erythema is more difficult to appreciate in darker skin
types).
Dosimetric information was collected through medical physics data forms completed by dosimetrists at each participating
site, as well as composite dose-volume histograms and DICOM
(Digital Imaging and Communications in Medicine)–formatted
files of the actual treatment plans that were uploaded to MROQC
for each patient. These sources provided the information regarding fractionation schedule (which we considered, as in our previous work, to be hypofractionated if at least some radiotherapy
fractions to the whole breast were >2 Gy in size—95% of these
were 2.6-2.7 Gy; patients for whom all radiotherapy fractions to
the whole-breast field were ≤2 Gy were considered to have received conventional fractionation—62.9% of these were 1.8 Gy
and 37.1% were 2.0 Gy), whether nodes were treated, mean breast
dose, maximum dose to 1 cm3 of breast volume, and whether a
boost was delivered.
920

Analysis
Two outcome measures were designated as co–primary end
points for toxicity analyses a priori: patient-reported breast
pain and physician-assessed moist desquamation. We first
described the sample, stratified by fractionation schedule,
for a number of key sociodemographic, clinical, and treatment factors: age, race, diabetes mellitus, hypertension,
breast volume, separation distance from breast tangent
entry to exit (which affects the ability to achieve homogeneous dose), body mass index, T stage, laterality, chemotherapy use, hormone therapy use, whether nodes were
treated, mean breast dose, maximum dose to 1 cm3 of breast
volume, and whether a boost was delivered. We then evaluated the maximum toxicity rating reported during treatment
through 7 days after treatment, as well as during a 6-month
follow-up period (8-210 days after treatment), for each
physician-assessed and patient-reported toxic effect in turn.
We compared each toxicity outcome between patients
receiving conventional fractionation and hypofractionation
after adjustment for the same set of potentially confounding
sociodemographic, clinical, and treatment factors, using
either a mixed-effects cumulative logit or mixed-effects
logistic model depending on the levels of the outcome
evaluated. The mixed-effects extension to standard linear
models allows for the creation of hierarchical linear models
in which the effects at the patient level can be nested within
institution, and in which the independent effect of any given
institution is not of interest, but rather, of interest is the generalization to the population of all possible institutions.23-25
In this article, potentially confounding covariates at the
patient level were modeled as fixed effects whereas institution was modeled as a random effect. P ≤ .05 was considered
statistically meaningful.
Finally, we conducted a sensitivity analysis within a more
homogeneous subgroup of the overall study sample to evaluate consistency with findings in the larger cohort. Specifically, we evaluated the distribution of the 2 co–primary end
points (patient-assessed breast pain and physician-assessed
moist desquamation) within the subgroup of patients who did
not undergo regional nodal irradiation and who did receive
boost treatment, and we constructed models as described in
the Methods section within this smaller subgroup.

Results
Table 1 presents the characteristics of the 2309 patients in the
study cohort, all of whom underwent lumpectomy and adjuvant radiotherapy to the whole breast and were registered in
MROQC from October 2011 through June 2014. Of these patients, 578 received hypofractionated whole-breast radiotherapy, of whom 347 (60%) received boost, and 1731 received conventionally fractionated whole-breast radiotherapy,
of whom 1608 (93%) received boost. As shown in Table 1, patients who received hypofractionation were older and of somewhat smaller body habitus, with smaller tumors and less frequency of nodal involvement, nodal radiation treatment, and
chemotherapy receipt.
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Table 1. Sample Description Stratified by Fractionation Schedule

Characteristic

Total
Population
(n = 2309)

Conventional
Fractionation
(n = 1731)

Hypofractionation
(n = 578)

P Value

Age, y
Mean (SD)

61.2 (11.1)

59.8 (10.8)

65.5 (11.0)

No. (%)
≤50

403 (17.5)

349 (20.2)

54 (9.3)

51-60

659 (28.6)

535 (30.9)

126 (21.8)

61-70

743 (32.2)

556 (32.1)

188 (32.5)

>70

501 (21.7)

291 (16.8)

210 (36.3)

White

1697 (73.6)

1253 (72.4)

445 (77.0)

Black

431 (18.7)

343 (19.8)

91 (15.7)

Other

171 (7.4)

131 (7.6)

39 (6.8)

<.001

Race

Not reported
Separation distance,
mean (SD), cm
Breast volume,
mean (SD), cm3

.04

6 (0.3)

4 (0.2)

3 (0.5)

22.7 (3.9)

23.0 (4.0)

21.9 (3.3)

1197 (693)

1270 (729)

<.001a
<.001a

980 (513)

BMI
Mean (SD)

30.3 (7.1)

30.8 (7.4)

28.7 (6.1)

≤25.0

574 (24.9)

410 (23.7)

164 (28.4)

25.1-30.0

652 (28.2)

452 (26.1)

200 (34.6)

30.1-35.0

530 (23.0)

410 (23.7)

120 (20.8)

>35.0

506 (21.9)

428 (24.7)

78 (13.5)

No. (%)

Not reported
Diabetes mellitus,
No. (%)
Hypertension,
No. (%)

<.001

47 (2.0)

31 (1.8)

16 (2.8)

353 (15.3)

275 (15.9)

78 (13.5)

.16

1152 (49.9)

849 (49.1)

303 (52.4)

.16

495 (21.4)

373 (21.6)

122 (21.1)

T stage, No. (%)
Tis
T0

7 (0.4)

1 (0.2)

T1

1341 (58.1)

8 (0.4)

947 (54.8)

394 (68.1)

T2

415 (18.0)

361 (20.9)

54 (9.3)

T3/T4

29 (1.3)

25 (1.4)

4 (0.7)

Not reported

21 (0.9)

18 (1.0)

3 (0.5)

<.001

N stage, No. (%)
NX

375 (16.2)

267 (15.4)

108 (18.6)

N0

1539 (66.7)

1101 (63.7)

438 (75.8)

N1

301 (13.0)

274 (15.8)

27 (4.7)

N2/N3

69 (3.0)

68 (3.9)

1 (0.2)

Not reported

25 (1.1)

21 (1.2)

4 (0.7)

Left breast

1179 (51.1)

894 (51.7)

285 (49.3)

Right breast

1130 (48.9)

837 (48.4)

293 (50.7)

Chemotherapy,
No. (%)

700 (30.3)

627 (36.2)

73 (12.6)

<.001

1580 (68.4)

1189 (68.7)

391 (67.7)

.61

293 (12.7)

286 (16.5)

7 (1.2)

<.001

<.001

Laterality, No. (%)

Hormone therapy,
No. (%)
Nodes treated as part
of plan, No. (%)

.37

(continued)
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Table 1. Sample Description Stratified by Fractionation Schedule (continued)

Characteristic

Total
Population
(n = 2309)

Conventional
Fractionation
(n = 1731)

Hypofractionation
(n = 578)

P Value

Mean dose to the
breast, Gyb
Mean (SD)

50.4 (4.0)

52.1 (2.8)

45.3 (2.5)

No. (%)
≤48.0

578 (25.0)

95 (5.5)

483 (83.6)

48.1-51.0

590 (25.6)

522 (30.2)

68 (11.8)

51.1-53.5

566 (24.5)

548 (31.7)

18 (3.1)

>53.5

551 (23.9)

549 (31.7)

2 (0.4)

24 (1.0)

17 (1.0)

7 (1.2)

60.8 (6.5)

63.7 (3.7)

Not reported

<.001

Hot spot: maximum dose
to 1 cm3 of the breast, Gyb
Mean (SD)

52.1 (5.3)

No. (%)
≤57.0

574 (24.9)

123 (7.1)

451 (78.0)

57.1-63.0

409 (17.7)

292 (16.9)

117 (20.2)

63.1-65.0

733 (31.8)

731 (42.2)

2 (0.4)

>65.0

569 (24.6)

568 (32.8)

1 (0.2)

24 (1.2)

17 (1.0)

7 (1.2)

1955 (84.7)

1608 (92.9)

347 (60.0)

Not reported
Boost delivered

Table 2 demonstrates the maximum physician-assessed toxic
effects during treatment among patients treated with each fractionation approach. We observed substantial differences in
physician-reported CTCAE scores for pain, dermatitis, and skin
induration, found to be statistically significant even after adjustment for multiple confounding sociodemographic, clinical, and
treatment factors as detailed in the Methods section and table
footnote. Specifically, patients who received conventional fractionation were more likely to be rated as having moderate or severe (grade ≥2) breast pain (20.0% vs 5.9%; adjusted odds ratio
[OR], 1.88 [95% CI, 1.24-2.84]; P = .003), at least grade 2 radiation dermatitis (62.6% vs 27.4%; adjusted OR, 2.42 [95% CI, 1.553.76]; P < .001), skin induration (21.1% vs 13.7%; adjusted OR, 1.98
[95% CI, 1.15-3.42]; P = .01), and chest wall pain (18.5% vs 6.8%;
adjusted OR, 4.83 [95% CI, 2.54-9.20]; P < .001). Patients receiving conventional fractionation were more likely to have experienced moist desquamation (28.5% vs 6.6%; adjusted OR, 2.78
[95% CI, 1.54-5.03]; P < .001) and dry desquamation (58.8% vs
18.7%; adjusted OR, 2.83 [95% CI, 1.76-4.53]; P < .001) during
treatment. Overall, patients receiving conventional fractionation
were much more likely to experience at least 1 grade 2 or greater
toxic effect during treatment than those treated with hypofractionation (67.7% vs 32.0%; adjusted OR, 2.24 [95% CI, 1.40-3.59];
P < .001).
Similar differences were observed for patient-reported
outcomes. Table 3 demonstrates the maximum patientreported toxic effects during treatment, by fractionation
approach, in the 1723 patients who consented and completed patient-reported outcomes questionnaires. Patients
treated with conventional fractionation had increased maximum patient-reported pain, desquamation, fatigue, and
bother related to burning/stinging, hurting, and swelling.
Specifically, patients who received conventional fraction922

<.001

<.001

Abbreviation: BMI, body mass index,
calculated as weight in kilograms
divided by height in meters squared.
a

Wilcoxon rank-sum test, comparing
medians.

b

Metric taken from the composite
dose-volume histogram.

ation were more likely to have reported moderate to severe
breast pain (41.1% vs 24.2%; adjusted OR, 1.92 [95% CI, 1.252.96]; P = .003), moist desquamation (25.7% vs 3.8%;
adjusted OR, 4.91 [95% CI, 2.35-10.28]; P < .001), dry desquamation (51.8% vs 12.2%; adjusted OR, 4.33 [95% CI, 2.497.53]; P < .001), frequent (“often” or “always”) bother from
burning or stinging of the skin of the treated breast (38.7% vs
15.7%; adjusted OR, 2.38 [95% CI, 1.39-4.06]; P = .002), frequent bother from the treated breast hurting (33.5% vs
16.0%; adjusted OR, 2.50 [95% CI, 1.44-4.33]; P = .001), frequent bother from swelling of the treated breast (29.6% vs
15.7%; adjusted OR, 1.88 [95% CI, 1.08-3.28]; P = .03), and
significant fatigue (29.7% vs 18.9%; adjusted OR, 1.87 [95%
CI, 1.11-3.15]; P = .02). No significant differences were
observed for patient-reported satisfaction with radiation
treatment with either fractionation approach.
In a sensitivity analysis conducted within a more
homogenous subgroup of patients treated without regional
nodal irradiation and with boost treatment, we observed
qualitatively similar findings in the distribution of our
co–primary end points. Specifically, among 1679 patients in
this subgroup who were evaluable for physician-assessed
toxic effects (1337 treated with conventional fractionation
and 342 with hypofractionation), we observed rates of moist
desquamation similar to those in the overall sample (27.8%
among those treated with conventional fractionation and
8.2% among those treated with hypofractionation); this difference was not statistically significant (P = .06) in the
multiple-variable models within this smaller subgroup.
Among 1309 patients in this subgroup who were evaluable
for patient-reported outcomes (1033 treated with conventional fractionation and 276 with hypofractionation), we
observed similar rates of breast pain (29.2% moderate and
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Table 2. Maximum Physician-Assessed Toxic Effects During Treatment Period
No. (%)

Toxic Effect

Conventional
Fractionation
(n = 1731)

Hypofractionation
(n = 578)

P Valuea

Odds Ratio
(95% CI)a

Breast pain
0

339 (19.6)

243 (42.0)

1

1046 (60.4)

301 (52.1)

2

320 (18.5)

31 (5.4)

3

26 (1.5)

3 (0.5)

0

818 (47.3)

400 (69.0)

1

804 (46.5)

171 (29.6)

2

109 (6.3)

7 (1.2)

.003

1.88 (1.24-2.84)

.09

1.44 (0.94-2.21)

<.001

2.42 (1.55-3.76)

.53

0.87 (0.56-1.35)

.01

1.98 (1.15-3.42)

<.001

4.83 (2.54-9.20)

.57

1.55 (0.35-6.84)

Lymphedema of breast

Radiation dermatitis
0

18 (1.0)

35 (6.0)

1

629 (36.4)

385 (66.6)

2

1053 (60.8)

157 (27.2)

3

31 (1.8)

1 (0.2)

0

1033 (59.8)

366 (63.3)

1

685 (39.6)

202 (35.0)

2

11 (0.6)

Pruritus

9 (1.6)

3

0

1 (0.2)

Missing

2

0

Skin induration
0

1364 (78.9)

499 (86.3)

1

332 (19.2)

76 (13.2)

2

32 (1.9)

3 (0.5)

Missing

3

0

Chest wall pain
0

1412 (81.6)

539 (93.2)

1

290 (16.8)

39 (6.8)

2

27 (1.6)

3

2 (0.1)

1+

319 (18.5)

39 (6.8)

1728 (99.9)

578 (100)

0
0

Pericarditisb
0
1

2 (0.1)

0

Missing

1

0

Pericardial effusionsb
0
1
Missing

1728 (99.9)

578 (100)

1 (0.1)

0

2

0

Dyspnea
0

1683 (97.4)

569 (98.6)

1

41 (2.4)

5 (0.9)

2

4 (0.2)

3 (0.5)

Missing

3

1

Pleuritic painb
0

1723 (99.7)

576 (99.7)

1

4 (0.2)

2 (0.4)

2

1 (0.1)

0

Missing

3

0
(continued)
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Table 2. Maximum Physician-Assessed Toxic Effects During Treatment Period (continued)
No. (%)

Toxic Effect

Conventional
Fractionation
(n = 1731)

Hypofractionation
(n = 578)

1724 (99.7)

577 (99.8)

P Valuea

Odds Ratio
(95% CI)a

Pneumonitisb
0
1

2 (0.1)

1 (0.2)

2

3 (0.2)

0

Missing

2

0

Fatigue
0

234 (13.5)

165 (28.6)

1

1288 (74.4)

390 (67.5)

2

204 (11.8)

23 (4.0)

3

5 (0.3)

.12

1.46 (0.91-2.35)

0

Maximum CTCAE-graded toxic
effects (of those measured above)
0

3 (0.2)

8 (1.4)

1

557 (32.2)

385 (66.6)

2

1115 (64.4)

181 (31.3)

3

56 (3.2)

4 (0.7)

2+

1171 (67.7)

185 (32.0)

Absent

1237 (71.5)

540 (93.7)

Present

493 (28.5)

38 (6.6)

Absent

714 (41.2)

470 (81.3)

Present

1017 (58.8)

108 (18.7)

<.001

2.24 (1.40-3.59)

<.001

2.78 (1.54-5.03)

<.001

2.83 (1.76-4.53)

a

Adjusted for breast volume,
separation distance, body mass
index, age, race, diabetes mellitus,
hypertension, T stage, laterality,
chemotherapy use, hormone
therapy use, whether nodes were
treated, mean breast dose,
maximum dose to 1 cm3 of breast
volume, and whether a boost was
delivered using either a cumulative
logit or logistic model depending on
the levels of the outcome.

b

Not enough events to adjust for
effects of covariates.

Desquamation
Moist

Dry

10.9% severe pain with conventional fractionation vs 23.9%
moderate and 5.1% severe pain with hypofractionation); this
difference remained statistically significant (P = .01) even in
this smaller subgroup.
eTable 1 in the Supplement reports the maximum physician-assessed toxic effects observed from 8 to 210 days after
treatment in the 1781 patients who had a physician follow-up
visit and assessment during that period. We observed, as expected, low rates of maximal toxic effects during this period.
There were no significant differences in maximum physicianassessed toxic effects reported during follow-up, except that
patients treated with conventional fractionation were less likely
to have skin induration (15.5% vs 18.8%; adjusted OR, 0.40
[95% CI, 0.19-0.85]; P = .02). Finally, eTable 2 in the
Supplement presents the maximum patient-reported toxic effects during the posttreatment follow-up period; no significant differences were observed between patients receiving conventional fractionation and those receiving hypofractionation.

Discussion
In this large comparative analysis conducted in a prospective
multicenter cohort of patients with breast cancer treated with
adjuvant whole-breast radiotherapy after lumpectomy, we observed substantial differences by fractionation schedule in both
physician-assessed and patient-reported acute toxic effects, in924

cluding pain, fatigue, and skin reaction/bother during radiation treatment, but similar experiences after treatment. This suggests that the selection of radiation fractionation schedule may
affect the incidence of acute, treatment-related toxic effects of
adjuvant whole-breast radiotherapy, which may compromise
patients’ quality of life during this challenging period.
Considerable evidence has accumulated, particularly
over the past decade, regarding the efficacy and safety of
hypofractionated whole-breast radiation therapy. Randomized trials from Canada 1 and Great Britain 2 have demonstrated equivalent tumor control, as well as a possible
reduction in late toxic effects in patients receiving hypofractionated schedules of 40 to 42.5 Gy in 15 to 16 fractions,
compared with the conventional fractionation schedule of
50 Gy in 25 fractions.
The decision to reduce the total dose is related to the
observation of substantial toxic effects in older studies of
hypofractionated whole-breast radiotherapy that maintained total dose in conjunction with higher dose per
fraction.12 Evidence from laboratory, animal, and clinical
studies suggests that fraction size has a larger impact on late
effects than acute effects of radiotherapy.26-28 The linearquadratic model of the relationship between total isoeffective dose and dose per fraction addresses the observation
that cells from late-responding tissues have survival curves
that are more curved in shape (with a lower α to β ratio) than
those from early-responding tissues. This means that for a
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Table 3. Maximum Patient Reported Toxic Effects During the Treatment Period

Toxic Effect

Conventional
Fractionation
(n = 1297)

Hypofractionation
(n = 426)

P Valuea

Odds Ratio
(95% CI)a

Breast pain (0-10)
Mean (SD)

3.4 (2.7)

2.2 (2.3)

Median (range)

3 (0-10)

2 (0-10)

164 (12.6)

118 (27.7)

Mild (1-3)

601 (46.3)

205 (48.1)

Moderate (4-7)

386 (29.8)

86 (20.2)

Severe (8-10)

146 (11.3)

17 (4.0)

Absent

964 (74.3)

410 (96.2)

Present

333 (25.7)

16 (3.8)

Absent

625 (48.2)

374 (87.8)

Present

672 (51.8)

52 (12.2)

No

812 (62.6)

340 (79.8)

Yes

485 (37.4)

86 (20.2)

No

795 (61.3)

359 (84.3)

Yes

502 (38.7)

67 (15.7)

No

1062 (81.9)

375 (88.0)

Yes

235 (18.1)

51 (12.0)

No

862 (66.5)

358 (84.0)

Yes

435 (33.5)

68 (16.0)

No

913 (70.4)

359 (84.3)

Yes

384 (29.6)

67 (15.7)

No

1143 (88.1)

404 (94.8)

Yes

154 (11.9)

22 (5.2)

No

1065 (82.1)

397 (93.2)

Yes

232 (17.9)

29 (6.8)

No

1074 (82.8)

399 (93.7)

Yes

223 (17.2)

27 (6.3)

No. (%)
None (0)

.003

1.92 (1.25-2.96)

<.001

4.91 (2.35-10.28)

<.001

4.33 (2.49-7.53)

.44

1.22 (0.73-2.03)

.002

2.38 (1.39-4.06)

.68

0.87 (0.46-1.65

.001

2.50 (1.44-4.33)

.03

1.88 (1.08-3.28)

.74

1.15 (0.51-2.61)

.21

1.57 (0.78-3.16)

.26

1.52 (0.74-3.06)

Moist desquamation,
No. (%)

Dry desquamation,
No. (%)

Bothered “All the Time” or “Often,”
No. (%)
Itching of the skin of your treated
breast

Burning or stinging of the skin
of your treated breast

Skin color changes in the treated
breast

Your treated breast hurting

Swelling of your treated breast

The effects of your skin reaction to
radiation on your interactions with
others

The effects of your skin reaction to
radiation on your daily activities

Your skin reaction to radiation
making it hard to work or do
what you enjoy

(continued)
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Table 3. Maximum Patient Reported Toxic Effects During the Treatment Period (continued)
Conventional
Fractionation
(n = 1297)

Hypofractionation
(n = 426)

No

1130 (89.1)

394 (94.0)

Yes

139 (10.9)

25 (6.0)

Toxic Effect

P Valuea

Odds Ratio
(95% CI)a

In General, During the Last 4 Weeks,
“Always” or “Most of the Time”
Did You, No. (%)b
Feel that your radiation therapy
limited your daily
activities?

Not answered

28

.68

1.19 (0.53-2.66)

.20

1.59 (0.78-3.25)

.83

1.11 (0.43-2.86)

.62

1.20 (0.59-2.41)

.02

1.87 (1.11-3.15)

7

Feel bothered by the side effects
of your radiation treatment?
No

1065 (82.1)

383 (92.5)

Yes

201 (15.5)

31 (7.5)

Not answered

31

12

Feel upset about the side effects
of your radiation treatment?
No

1164 (91.9)

399 (95.9)

Yes

102 (8.1)

17 (4.1)

Not answered

31

10

Feel that your radiation therapy
was worth doing even with the
side effects?
No

160 (12.8)

67 (16.6)

Yes

1089 (87.2)

336 (83.4)

Not answered

48

23

Think about stopping your radiation
therapy?b
No

1233 (98.0)

Yes

25 (2.0)

Not answered

39

409 (98.8)
5 (1.2)
12

Feel significant fatigue?
No

881 (70.3)

340 (81.2)

Yes

373 (29.7)

79 (18.9)

Not answered

43

7

Feel pain in your breast
or chest wall?
No

1059 (85.2)

376 (91.5)

Yes

184 (14.8)

35 (8.5)

Not answered

54

.051

20.6 (1.00-4.24)

15

Worry about your skin reaction
to the radiation?
No

1020 (81.9)

378 (91.1)

Yes

225 (18.1)

37 (8.9)

Not answered

52

.12

1.71 (0.87-3.35)

.27

1.66 (0.67-4.05)

11

Feel distressed about
the appearance
of your chest?
No

1115 (89.1)

399 (95.9)

Yes

137 (10.9)

17 (4.1)

Not
answered

45

10
(continued)
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Table 3. Maximum Patient Reported Toxic Effects During the Treatment Period (continued)

Toxic Effect

Conventional
Fractionation
(n = 1297)

Hypofractionation
(n = 426)

P Valuea

Odds Ratio
(95% CI)a

.54c

0.86 (0.54-1.38)c

.58d

1.14 (0.71-1.86)d

.25e

1.46 (0.76-2.79)e

.43f

0.72 (0.32-1.64)f

Overall, my radiation
therapy treatments
have beenb
Very convenient

305 (24.3)

110 (26.4)

Convenient

369 (29.5)

125 (30.1)

Neutral

389 (31.1)

115 (27.6)

Inconvenient

125 (10.0)

41 (9.9)

Very inconvenient

64 (5.1)

25 (6.0)

Not answered

45

10

Overall, how bothered have you been
by the amount of time it took to
have your radiation therapy
treatments?b
Very

9 (0.7)

Quite

13 (1.0)

4 (1.0)

Moderately

84 (6.7)

13 (3.1)

A little

280 (22.3)

97 (23.2)

Not at all

870 (69.3)

302 (72.3)

Not answered

41

2 (0.5)

8

Overall, are the side effects of
radiation therapy as you expected?b
Much better

345 (27.5)

187 (45.0)

Somewhat better

387 (30.9)

126 (30.3)

Exactly

241 (19.2)

66 (15.9)

Somewhat worse

243 (19.4)

35 (8.4)

Much worse

37 (3.0)

2 (0.5)

Not answered

44

a

Adjusted for breast volume,
separation distance, body mass
index, age, race, diabetes,
hypertension, T stage, laterality,
chemotherapy use, hormone
therapy use, whether nodes were
treated, mean breast dose,
maximum dose to 1 cm3 of breast
volume, and whether a boost was
delivered using either a cumulative
logit or logistic model depending on
the levels of the outcome.

b

Reported only at end of treatment.

c

Comparing “Very convenient” and
“Convenient” vs all else between
fractionation groups.

d

Comparing any reported bother vs
“Not bothered at all” between
fractionation groups.

e

Comparing “Somewhat” and “Much”
worse than expected to all else
between fractionation groups.

f

Comparing “Very satisfied” and
“Satisfied” vs all else between
fractionation groups.

g

Comparing “Yes, definitely” and
“Probably yes” vs all else between
fractionation groups.

10

Overall, how satisfied are you with
your radiation therapy treatment?b
Very satisfied

727 (57.9)

266 (63.8)

Satisfied

407 (32.5)

125 (30.0)

Neutral

108 (8.6)

23 (5.5)

2 (0.2)

1 (0.2)

Very dissatisfied

10 (0.8)

2 (0.5)

Not answered

43

9

Dissatisfied

Taking everything into consideration,
if given the choice again, would you
decide to have radiation therapy?b
Yes, definitely

785 (62.7)

272 (64.9)

Probably yes

327 (26.1)

109 (26.0)

Don’t know

118 (9.4)

34 (8.1)

Probably not

17 (1.4)

Definitely not

6 (0.5)

Not answered

44

4 (1.0)

1.38 (0.67-2.87)g

0
7

given total dose, administration of higher doses per fraction
would be expected to increase late toxic effects more substantially than acute toxic effects. Traditionally, tumors have
been believed to resemble early-responding normal
tissues,29 but recently, it has become apparent that breast
cancer cells may actually have an α to β ratio more similar to
jamaoncology.com

.39g

that seen in late-responding normal tissues,15 meaning that
equivalent tumor control might be possible in a hypofractionated regimen even if total dose were decreased.
The decreasing of total dose, in turn, might have important implications for acute toxic effects, but little clinical evidence has existed prior to the present study to document this.
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The British FAST trial collected data on acute toxic effects in a
subset of 327 patients, given reports of unusually severe reactions in 3 patients treated with the highly accelerated schedule of hypofractionation explored in that trial (28.5 or 30 Gy
administered in 5 once-weekly fractions). The 3 reported events
were deemed on review to have been neither unusual nor severe; and overall, grade 2 and 3 skin reactions appeared more
frequent with conventional fractionation.30 Documentation of
the acute toxic effects of more commonly used hypofractionation schedules has been more limited. The START trials only
documented that “unusually marked” acute reactions were
rare and not more common with hypofractionation.16,17 Preliminary abstract presentations from Denmark, China, Nepal,
and India have been limited by small samples and measurement concerns.31-34 Therefore, there remains considerable
need for data regarding the acute toxic effects of hypofractionated radiotherapy, particularly from the patient’s own
perspective.
The only data available to our knowledge that describe
patient-reported outcomes of hypofractionation in comparison to conventional fractionation are the preliminary results
recently presented from a small randomized trial at a single
institution,35 which were consistent with the findings of this
cohort study. We believe that these 2 studies complement
one another (with the randomized trial offering the highest
quality evidence of a causal relationship, and the present
observational study offering the best external validity to
generalize to real-world practice). Together, these studies
offer relatively persuasive evidence that hypofractionation is
indeed causally related to a reduction in acute toxic effects
during breast radiation therapy, as actually practiced in the
community.
The greatest strength of this study is its prospective collection of detailed clinical, toxicity, and treatment planning data
from a large number of women treated in real-world radiation oncology practices. Increased awareness of the limitations of general cancer registries36,37 in obtaining information on the very administration of radiotherapy itself, let alone
the details necessary to evaluate questions relating to the comparative effectiveness of different radiation treatment approaches, has motivated growing interest in the development of radiation oncology–specific registries.38 Although there
are advantages to considering data from real-world practice and
large numbers of patients from whom detailed physicianassessed and patient-reported measures have been collected, there are also associated limitations. First, the size and
scope of such an endeavor as MROQC make it impossible to
firmly standardize the timing of assessments beyond the immediate treatment period. Although it is reassuring that all patients included in the present analysis had an end-oftreatment evaluation, it is possible that patients treated with
hypofractionation had a delayed incidence of their most severe acute toxic effects, which might have been missed as a
result of the lack of a routine weekly visit after completion of
treatment. We can, however, reassure the reader that there was
no systematic difference in the distribution of timing of follow-up assessments by fractionation approach (eAppendix 3
in the Supplement). Moreover, we did collect information re928

garding toxic effects in any patients who were seen after treatment for any reason, including unscheduled short-interval toxicity management visits—so severe toxic effects prompting a
visit would have been noted in the follow-up period. The general infrequency of toxic effects during the follow-up period
and the similarities across numerous outcome measures for
patients treated with each fractionation approach suggest that
major differences in posttreatment toxicities are unlikely. Still,
further research would be useful to explore posttreatment toxic
effects in greater detail, including verification of the observation of a slightly higher rate of induration (albeit mostly mild)
in the hypofractionation subgroup during follow-up in this
study.
Another limitation of this study relates to its observational nature; patients were not randomly allocated to hypofractionation vs conventional fractionation, and most patients were treated with conventional fractionation. Some of
the factors that affect selection of fractionation (including
smaller body habitus and lack of chemotherapy administration) may themselves affect likelihood of acute toxic effects,
such that the association observed might be confounded rather
than causal. Nevertheless, MROQC includes information on
many potential confounding factors, and the associations observed persisted even after adjustment for all of these. That
these results are consistent with those of a randomized trial
suggests that the associations observed are likely to be causal
in nature. The main strength of this study is its ability to
complement the findings of randomized trials to demonstrate that acute toxic effects seem to be less frequent and/or
severe with hypofractionation as applied in routine practice
in the community.
The slow and nonuniform uptake of hypofractionated
breast radiotherapy has recently become the subject of considerable attention.9-11,39 Studies have shown that hypofractionation remains underused, even in analyses of patients
treated well after the issuance of consensus guidelines,3 mature long-term evidence from clinical trials, and the encouragement of the American Society for Radiation Oncology’s
Choosing Wisely campaign.4 It is critical to recognize that hypofractionation not only provides equivalent long-term tumor control in selected patients at considerably lower cost and
greater convenience, but it may also represent a more tolerably administered approach. Patients and physicians who may
be cautious about embracing new techniques should consider carefully the evidence in the present study. Reducing the
severity and frequency of acute toxic effects from breast radiotherapy has been cited as the justification for costly and
complex treatment planning approaches, including intensitymodulated radiotherapy. The present results are striking insofar as they suggest that similar or even greater gains in tolerability might be possible with a simple adjustment to dosing
schedules that is also less costly and more convenient.

Conclusions
This study provides information about the frequency and
nature of acute toxic effects during whole-breast hypofrac-
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tionated radiotherapy, highly relevant to women considering this treatment and absent from the literature to date.
Given the importance of patient-reported outcomes
and generalizable evidence of comparative effectiveness
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